ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

CT-P13 SC Auto-Injector

Also written as “CT-P13 SC Auto-injector”.

Its studies are mostly in Arthritis, Rheumatoid, led by Celltrion.

Furthest: phase 3, since Dec 10, 20242 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Celltrion20 open or runningphase 3since Dec 10, 2024Feb 21, 2018none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 21, 2018First study: phase 1 study in Health, SubjectiveFirst studyNCT03446976 · 218 enrolled · United States
  2. Dec 10, 2024Phase 3 study in Moderately to Severely Active Rheumatoid ArthritisNCT06738719 · 192 enrolled · Poland

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06738719Moderately to Severely Active Rheumatoid Arthritis · Poland3CompletedJun 25, 2025192
NCT03446976Health, Subjective · United States1CompletedJul 26, 2018218

How it is read

Names in the registry

  • “CT-P13 SC Auto-Injector”, 1 entry
  • “CT-P13 SC Auto-injector”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.